Razoxane (Razoxin), has been reported to have antimetastatic, antitumour and radiosensitising activities in pre-clinical models. Clinical evidence of therapeutic value in combination with radiotherapy is, however, tenuous.
This study was designed to provide evidence of therapeutic efficacy of razoxane as an antitumour or radiosensitising agent in the palliative treatment of locally advanced bronchial carcinoma.
Patients with untreated non-small cell or unknown histology and no clinical evidence of metastatic disease, referred to the Department of Radiotherapy in Birmingham for palliative radiotherapy after January 31, 1980 were eligible. Those patients with evidence of pleural effusion or distant metastases and those who had received previous radiotherapy or chemotherapy were not eligible. Baseline assessments included history, physical, performance status, chest X-ray, haematology and liver function tests. Other investigations were performed when indicated on clinical grounds. The design of this trial, which was double-blind, placebo controlled and utilised sequential analysis, has been previously described (Jones et al., 1982) . Prospective randomisation was achieved using the variance method of Freedman & White (1976) which balanced for the stratification factors histology, history of previous surgery and performance status.
Razoxane 125mg orally twice daily was started 3 days before, and continued during radiotherapy. After radiotherapy razoxane was continued on 5 days each week at the discretion of the physician in charge. No direct assessment of patient compliance was made. The protocol was later modified, based on the reported experience of others to allow discontinuation of therapy if the white cell count was <2000 x 1091 -. Placebo tablets, indistinguishable from razoxane, were administered in an identical way. Radiotherapy was given with palliative intent and was usually 3000-3500 cGy in 10-15 fractions over 2-3 weeks. Field sizes, to include tumour mass and mediastinum, were usually 12cm x 15cm. Patients were followed monthly for 3 months and 3 monthly thereafter by study staff.
The sequential design involved a comparison of the survival experiences of the two groups, using log rank analysis after every 12 deaths. The design was constructed so that significance (at the 5% level, one-sided alternative) would be observed with probability 0.9 if the hazard on razoxane was 0.8 of that on placebo.
The inspections required by the sequential design showed from the first that the razoxane group was experiencing the poorer survival. This was contrary to expectation. Fortunately, the sequential design picked up this inferiority quickly and enabled the trial to be terminated after only 8 inspections. At this time 148 patients had been treated, 102 had died and 1 patient was lost to follow-up. Median survival time in the razoxane group was 80 days and in the placebo group it was 175 days.
Because the trial was terminated as a result of the observed inferiority of razoxane, a standard log rank analysis is not valid. The appropriate analysis estimates the hazard ratio (razoxane: placebo) to be 1.76 with a 95% confidence interval of (1.16, 2.83). Razoxane was significantly inferior to placebo (P<0.05, two-sided alternative). The life table analysis of survival in each group at the termination of the study is shown in Figure 1 . Further details of the method of analysis are given in Section 5.3 of Whitehead (1983) .
Preliminary analysis of the data indicates that study groups are balanced with respect to The unequivocal difference in survival experience merits reporting of this preliminary analysis and the conclusions that razoxane is of no benefit and is significantly worse than placebo.
Myelosuppression and depression of humoral immunity in mice, have been described with razoxane. Although leucopaenia is more common in the razoxane group, initial analysis in this study does not indicate the cause of the adverse effect of razoxane.
We are aware of reports of 2 previous doubleblind, placebo-controlled trials of razoxane combined with radiotherapy by Bakowski et al. (1978) and Belloni et al. (1983) . One reported no benefit in operable cervical cancer, the other reported deletrious effects in head and neck cancer. This short communication describes the third such study and is the second to report detrimental effects when razoxane and radiation therapy are combined.
